Ercan, Dalia

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,589

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,013

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 869

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine

HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Cited by 663

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 378

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 368

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 294

Pharmacological targeting of the pseudokinase Her3

Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 205

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

Cortot, A. B., Repellin, C. E., Shimamura, T., Capelletti, M., Zejnullahu, K., Ercan, D., Christensen, J. G., Wong, K.-K., Gray, N. S., & Jänne, P. A. (2013) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 185

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 131